Search the whole station
From October 22 to October 25, 2024, Hengsai Biologicals participated in the 13th China Innovation and Entrepreneurship Competition (Guangdong Region) and the 12th Pearl River Angel Cup Science and Technology Innovation and Entrepreneurship Competition Finals organized by Guangdong Provincial Science and Technology Department, and won the second prize of the Growth Group.
This year's competition focuses on five industry directions: new-generation information technology, high-end equipment manufacturing, new materials, biomedicine, as well as new energy, new energy vehicles, energy saving and environmental protection.
Hengsai Biologicals participated in the competition for the first time this year, and had already won the second prize in the growth group of the Zhongshan City Final, and successfully advanced from the Zhongshan City Competition to the final of Guangdong Province and once again won a good result.
About China Innovation and Entrepreneurship Competition
China Innovation and Entrepreneurship Competition (CIEC) is one of the events with the longest history, largest scale and widest influence in China, and has been held for twelve consecutive years since its inception in 2012. Adhering to the tenet of "government guidance, public support and market assistance", the competition has attracted nearly 300,000 participating enterprises and teams, and the winning enterprises and teams have received a large number of government support, market financing and other services.
About Hengsai Bio
Founded in 2018, Hengsai Bio is a scientific and technological innovative enterprise and national high-tech enterprise dedicated to the research, development and industrialization of dendritic cell vaccines (DC vaccines). The company has successfully constructed the Eco-DCVax platform, aiming to break down the technical barriers to industrialization and develop global First-in-Class high-quality DC vaccine products with independent property rights that are safe, efficient and convenient to administer. The developed product, therapeutic dendritic cell vaccine, provides a new approach and strategy for the treatment of relapsed and refractory tumors, chronic viral infections, autoimmune diseases and other diseases that are in urgent need of effective clinical treatments.
Hengsai Bio's Shanghai R&D center will be put into operation in 2021, Zhongshan R&D center will be officially opened in October 2024, and a large R&D/production base is under construction. The company's debut pipeline, KSD-101, has successfully completed dual reporting in China and the U.S., and has been granted an IND license by the U.S. Food and Drug Administration (FDA), the first original dendritic cell vaccine (DC Vaccine) product in China to receive an IND approval from the U.S. FDA. The company has now established stable cooperative relationships with a number of domestic and foreign research institutions and tertiary hospitals to carry out clinical research and technical cooperation in order to comprehensively verify the clinical safety and efficacy of the DC vaccine.
2024 EHA | Prof. Chunrui Li: Focusing on China's original research power, the field of EBV-associated hematological oncology therapeutics is revitalized
View details
Hengsai Biologicals Completes Tens of Millions of Dollars in Series A+ Financing
View details
Exploring the Mystery of EBV and Tumor 丨Hengsai Biotechnology Shows Its Elegance on the International Academic Stage Again
View details
Kousai Biological Dendritic Cell Vaccine Drug Production and Research Project Groundbreaking Ceremony Successfully Held
View details
Hengsai Biotechnology
